Short Interest in Emergent BioSolutions Inc. (NYSE:EBS) Increases By 84.1%

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 8,230,000 shares, a growth of 84.1% from the September 15th total of 4,470,000 shares. Based on an average daily volume of 3,020,000 shares, the short-interest ratio is presently 2.7 days. Approximately 15.9% of the shares of the company are short sold.

Emergent BioSolutions Stock Performance

Shares of NYSE EBS traded up $0.30 during mid-day trading on Friday, hitting $8.75. The company had a trading volume of 1,272,170 shares, compared to its average volume of 3,610,860. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $15.10. The firm has a market cap of $458.52 million, a P/E ratio of -0.79 and a beta of 1.59. The business's 50-day simple moving average is $8.20 and its 200-day simple moving average is $6.77. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.06 and a quick ratio of 0.54.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($1.35). The firm had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. During the same quarter in the prior year, the business posted ($1.06) EPS. As a group, analysts predict that Emergent BioSolutions will post -1.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on EBS. Rodman & Renshaw reaffirmed a "buy" rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark reaffirmed a "buy" rating and set a $8.00 target price on shares of Emergent BioSolutions in a research report on Friday, August 16th.

Institutional Investors Weigh In On Emergent BioSolutions

Several institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC boosted its position in shares of Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 4,906 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Emergent BioSolutions during the second quarter valued at approximately $41,000. Verus Capital Partners LLC bought a new stake in shares of Emergent BioSolutions in the 2nd quarter valued at approximately $68,000. Avidian Wealth Solutions LLC acquired a new position in shares of Emergent BioSolutions in the 1st quarter worth approximately $33,000. Finally, Tidal Investments LLC acquired a new stake in Emergent BioSolutions in the 1st quarter valued at $34,000. Institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.